Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ONXX -- Ignore unavailable to you. Want to Upgrade?

To: C. K. Humphries who wrote (193)	5/9/1998 11:06:00 PM
From: Luke	Read Replies (1) \| Respond to of 810

hello. Ran across a sort-of related onyx news the other day (in April, that is): diaDexus Appoints Dr. William G. Gerber as President and CEO SANTA CLARA, Calif., April 9 /PRNewswire/ -- diaDexus, LLC today announced it has appointed William G. Gerber, M.D., as President and Chief Executive Officer. Dr. Gerber's business and clinical experience are vital elements in positioning diaDexus, a new company formed as a joint venture between SmithKline Beecham, Corporation and Incyte Pharmaceuticals, as a powerful force in the world of molecular diagnostics and pharmacogenomics. His management experience spans both the diagnostics and therapeutics industries. Dr. Gerber joins diaDexus from Onyx Pharmaceuticals, a biopharmaceutical company engaged in the discovery of cancer therapeutics, where he served as Vice President and Chief Operating Officer. From 1991-1995, he was President, Chiron Diagnostics, with operating and P&L responsibility. Prior to 1991, he held various positions of increasing responsibility with Cetus Corporation, culminating in his appointment as Senior Vice President and General Manager for the PCR division. Earlier in his career, Dr. Gerber was Medical Director, Health Services Division of Humana Corporation as well as a practicing physician. Dr. Gerber holds an M.D. from the School of Medicine, University of California, San Francisco Medical Center. "We are delighted to have Bill join diaDexus as President and CEO. With Bill's leadership and extensive experience, we are confident that diaDexus will emerge as a formidable competitor in molecular diagnostics and pharmacogenomics," said Dr. George Poste, Chief Science and Technology Officer, SmithKline Beecham, Corporation and Chairman of the Board of diaDexus, LLC. "I am excited to be associated with a company with the potential of diaDexus. In my opinion, diaDexus is superbly positioned to create a leadership position in the field of molecular diagnostics by combining the vitality of a new company with the substantial support of SmithKline Beecham and Incyte Pharmaceuticals, both acknowledged leaders in genomics and bioinformatics," said Dr. Gerber. diaDexus, located in Santa Clara, CA, is a new company formed as a joint venture between SB and Incyte, diaDexus is dedicated to the discovery and commercialization of novel molecular diagnostic products focused initially on disease detection instead of risk predisposition profiling. The company will develop novel tests for improved diagnosis, staging and patient stratification in infectious disease and oncology, and pharmacogenomic tests aimed at customizing the use of pharmaceuticals for specific subgroups of patients. SB and Incyte each hold a 50% equity interest in diaDexus. diaDexus has exclusive rights to develop diagnostic tests based on novel molecular targets and genetic alterations identified as part of SB's drug discovery efforts. SB has also exclusively licensed to diaDexus a number of novel diagnostic tests in late-stage clinical validation. Incyte provides diaDexus with non-exclusive access to its human and microbial databases, bioinformatics capabilities and certain array technologies. The two parent companies also contributed a variety of technologies and intellectual property rights. SOURCE diaDexus, LLC